U.S. Markets close in 17 mins

BG Medicine making progress on Galectin-3, says Ladenburg

After meeting with BG Medicine's management, Ladenburg thinks the company is making significant progress in repositioning Galectin-3 from a test for evaluating chronic heart failure to a test for evaluating hospitalization/re-hospitalization risk in acute heart failure patients. The firm expects this change to enhance the company's ability to obtain greater reimbursement for the product in the intermediate term. It reiterates a Buy rating on the shares.